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Summary 
Free peptide has been found to inhibit cytotoxic T  lymphocyte (CTL) activity, and veto cells 
bearing peptide-major histocompatibility complex (MHC) complexes have been found to in- 
activate CTL, but the two phenomena have not been connected.  Here we show that a com- 
mon mechanism may apply to both.  CD8 + CTL lines or clones specific for a determinant of 
the human immunodeficiency virus (HIV) 1 IIIB envelope protein gp160, P18IIIB, are inhib- 
ited by as little as 10 min exposure to the minimal 10-mer peptide, 1-10, within P18IIIB, free 
in solution, in contrast to peptide already bound to antigen-presenting cells (APC), which does 
not inhibit.  Several lines of evidence suggest that the peptide must be processed and presented 
by H-2D  a on the CTL itself to the specific T  cell receptor (TCR) to be inhibitory. The inhibi- 
tion was not killing, in that CTL did not kill SlCr-labeled sister CTL in the presence of free 
peptide,  and in mixing experiments with CTL lines of different specificities restricted by the 
same MHC molecule, D a, the presence of free peptide recognized by one CTL line did not in- 
hibit the activity of the other CTL line that could present the peptide. Also, partial recovery of 
activity could be elicited by restimulation with cell-bound peptide, supporting the conclusion 
that neither fratricide nor suicide (apoptosis) was involved. The classic veto phenomenon was 
ruled out by failure of peptide-bearing CTL to inactivate others.  Using pairs of CTL lines of 
differing specificity but similar MHC restriction,  each pulsed with the peptide for which the 
other is specific, we showed that the minimal requirement is simultaneous engagement of the 
TCR and class I MHC molecules of the same cell.  This could occur in single cells or pairs of 
cells  presenting  peptide  to  each  other.  Thus,  mechanistically the  inhibition  is  analogous  to 
veto, and might be called self-veto. As a clue to a possible mechanism, we found that free 1-10 
peptide induced apparent downregulation of expression of specific TCR as well as interleukin 2 
receptor, CD69, lymphocyte function-associated antigen 1, and CD8. This self-veto effect also has 
implications for in vivo immunization and mechanisms of viral escape from CTL immunity. 
T 
he  TCR  of CD8 +  class  I  MHC  molecule-restricted 
cytotoxic T  lymphocytes (CTL) binds a processed an- 
tigenic peptide, usually composed of 8-10 amino acids, fit- 
ted within the groove of a class I MHC  molecule situated 
on the cell surface (1). Although peptide added free in solu- 
tion may bind to the class I MHC molecule of the effector 
CTL, lysis of peptide-coated CTL by other CTL has been 
reported unlikely (2-4), probably because CTL are resistant 
to their own cytolytic mediators.  Nevertheless, we found 
that a free peptide  of optimal size  (I-10:  RGPGRAFVTI 
from HIV-1  gp160  envelope  glycoprotein)  (5,  6)  almost 
completely blocked the  specific CTL activity toward tar- 
gets presensitized with the same peptide when added in so- 
lution during the 4-6 h 51Cr release assay. 
Several recent  papers  have  described  similar inhibitory 
phenomena  by  free  antigenic  peptide  (7-11),  but  the 
mechanism of this inhibition is still controversial. Some pa- 
pers suggest self-destruction (suicide) (8, 9, 12), some argue 
CTL-CTL  killing  (fratricide)  (13),  and  some  indicate  a 
pronounced  but  transient  inhibition  or  inactivation  (an- 
ergy)  (14).  Also,  as  Su  et al.  (13)  point  out,  the  require- 
ments for killing may be different from those for anergy. A 
possibly related  phenomenon  was  seen  earlier  for  CD4 + 
MHC class II-restricted Th cells,  in which  exposure of T 
cell clones to high concentrations ofpeptide for >6 h  led 
to  an  anergic  state lasting at least  7  d,  although  the  cells 
were  not  killed  because  they  could  still  respond  to  IL-2 
(15-17). In this case, peptide had to be presented on class II 
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human  class  II  MHC-positive  T  cells themselves.  How- 
ever, subsequent studies showed that such anergy induced 
by antigen presented on T  cells was not due to lack of co- 
stimulation (18),  and so the  mechanism  was  distinct from 
that of anergy induced by antigen-MHC complexes in the 
absence ofcostimulation (19, 20). 
Another situation in which  CD8 +  CTL  are inactivated 
but not always killed is termed the veto phenomenon  (11, 
21-24).  The  veto  cell  is  a  cell  expressing  the  peptide- 
MHC  complex  recognized by  the  receptor  of the  CTL, 
which inactivates the  CTL  that  targets it.  Another CD8 § 
cell is the most effective type of veto cell, but the veto phe- 
nomenon does not require engagement of the antigen-spe- 
cific TCR  of the veto cell, only its class I MHC  molecules. 
Recent studies have shown that the CD8  molecule of the 
veto  cell  plays  a  role  by  binding  the  o~3  domain  of the 
MHC  class I molecule of the CTL being vetoed (24). This 
phenomenon has been studied largely in cases of CTL spe- 
cific for histocompatibility antigens (22),  but recently cells 
presenting defined peptides have been shown to veto (11). 
However, in contrast to the studies of free pepude inhibi- 
tion of CTL, CTL clones are resistant to the veto phenom- 
enon (23). Thus,  no connection has been made previously 
between the two phenomena. 
In this study, we show that the inhibition of CTL is ini- 
tiated by  the  binding of antigenic peptide for which  the 
CTL as specific to the MHC  molecules on the CTL's own 
surface,  and  is not  caused by either the  peptide presented 
only on other cells including saster CTL, or by direct inter- 
acnon of the TCR  with free peptide. Using pairs of CTL 
lines  of differing specificity but  similar MHC  restriction, 
each pulsed with the peptlde for which the other is specific, 
we show that the minimal requirement is simultaneous en- 
gagement of the TCR  and class I  MHC  molecules of the 
same cell. The transient anergy is associated with downreg- 
ulation of the TCR  and several accessory cell surface mole- 
cules. 
This mechanism of inhibition characterized here as remi- 
niscent of the veto mechamsm.  However,  it is not simply 
the classic veto phenomenon,  because CTL presenting the 
peptide to other CTL do not inhibit them. We suggest that 
indeed  the  inhibition  by  free  pepude  is analogous at  the 
molecular level  to  the  veto  phenomenon,  but  that  CTL 
clones require a stronger signal through their MHC  class l 
molecules, using a  TCR  rather than simply CD8  interac- 
tion with the c~3 domain.  Thus,  free peptide inhibition of 
CTL  clones  may  be  considered  a  process  of "self-veto." 
This self-veto phenomenon may be important not only for 
in vitro studies, but also in vivo for its possible effect on vi- 
ral persistence and CTL inactivation by viral products. 
Materials and Methods 
Animals.  BALB/c  (D  d,  L  d,  K d)  trace  were  obtained  from 
Charles River Japan Inc. (Tokyo, Japan) and B10.A (D  a, L  d, K k) 
from Sankyo Laboratory Inc. (Tokyo, Japan). Mice were used at 
6-12 wk of age. 
CTL Lines and Clones.  The CTL hne (LINE-IIIB) and clones 
specific  for  the  HIV-1  envelope  protein  of  the  lllB  isolate 
(gp160IIIB) were generated as described (25). Both the gpl60lllB- 
specific CTL line and the clones were restricted by the D a class I 
MHC  molecule  and  were  specific  for  an  immunodominant 
epltope P18IIIB (RIQRGPGRAFVTIGK). The mlmmal acnve 
peptide was shown to be the  10-mer, P18-l-10  (5, 6,  26). The 
CTL  line  (LINE-MN)  specific for the  HIV-1  envelope of the 
MN  isolate (gp160MN)  was  obtained from  vMN  (gp160MN- 
expressing recombinant vaccima virus)-immune BALB/c spleen 
cells  (27).  It was  stimulated with P18MN  (RIHIGPGRAFYT- 
TKN)-pulsed irradiated syngenelc spleen cells and wath rat ConA 
supernatant added on the second day and maintained by biweekly 
repetitive stimulation. 
Synthetic Peptides.  The  peptides are named according to the 
last  amino acid residue and the  length,  except for  the  onginal 
P18IIIB and P18MN peptides. Peptides were synthesized and pu- 
rified as described previously (25-27). 
mAbs.  The following mAbs were used: ann-CD4 (RL172.4) 
(28) for deplenng P18IIIB-speclfic I-Aa-resmcted (29) CD4 + Th 
cell hne (HT-4)  (6) and ant~-K  k (30) for depleting B10.A spleen 
cells with rabbit C  (Cederlane Laboratones Ltd.,  Homby, On- 
tario,  Canada);  FITC-labeled anti-CD3  (2C1l  [31]),  anti-lL- 
2Rc~ (32), anu-CD69 (33), or anti-V[3-8.1 (34), anti-D  a (r  do- 
mare)  (34-2-12 [35]), anu-L  a (30-5-7 [36]), and anti-K  a (31-3-4 
[36]) for cell surface staining. 
Inhibition of Serum Actiwty  upith Angiotensin-convertmg Enzyme 
(ACE) Inhibitor.  The ACE (EC3.4.15.1  peptidyl/dipeptide hy- 
drolase)-specific inhahitor  captopnl  (Sigma  Chermcal  Co.,  St. 
Louis, MO)  was dissolved in PBS at 100  p,M and added to the 
culture at 10 -5 M 30 rain before mLxmg with the inhibitory pep- 
tide. 
CTL Assay.  Cytotoxicity was assessed in a standard 5-h SICr 
release  assay as described previously (37),  with StCr-labeled tar- 
gets, as indicated m the figure legends. SEM oftriphcate cultures 
was always <5% (and often <3%) of the mean. 
FACS  ~ Analysis.  For direct one-color staining to determine 
the  effect  of free  peptide  treatment  of the  gp160IllB-specific 
CTL  lines or clones on  their surface  molecule expression,  lff  ~ 
cells  were  incubated at  37~  for  1  h  with  free  [-10  and  then 
washed  three times with  RPMI  1640  to  remove  free  peptide. 
Then,  1 p.g of each indicated FITC-labeled antibody was added 
to  the  cell pellet for a  40-rain incubation at 4~  All reagents 
were pretitered and used in amounts known to be saturating on 
positive controls. The  cells were washed three umes and resus- 
pended  at  106  cells/0.5  ml  in  PBS/BSA/azlde  for  analysis  by 
FACScan  |  analyzer (Becton  Dickinson  Immunochemastry Sys- 
tems, Mountain View, CA).  Dead and damaged cells were ex- 
cluded from the analysis by propidium Iodide gating. 
Results 
Free  Peptides  Inhibit  CTL  Activities  in  a  Dose-dependem 
Manner.  The  minimal  epitope  of CD8 +  CTL  lines  or 
clones specific for an immunodominant determinant of the 
HIV-1  IIIB  envelope  protein  gp160,  18IIIB  (315-329) 
(RIQRGPGRAFVTIGK),  presented by the murine class I 
MHC  molecule  H-2D d,  has  been  identified as  a  10-mer 
peptide,  1-10  (RGPGRAFVTI)  (5,  6,  26).  We  have  no- 
uced that we could not show a clear concentration depen- 
dence when the mimmal size free 1-10 was added together 
with S~Cr-labeled fibroblast targets during the 4-h assay, al- 
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tration  curve  (Fig.  1  A).  As a  possible explanation,  when 
we used peptide-pulsed targets, we observed that free 1-10 
strongly inhibited CTL activity even at very low concen- 
trations, whereas the longer peptide,  18IIIB, inhibited the 
activity only at  high  concentrations  (Fig.  1  A).  Similarly, 
high concentrations of free 18IIIB showed some inhibition 
when used with the unpulsed fibroblast targets. Similar re- 
suits  were  obtained  in  five  other  experiments,  including 
one with 1-10-pulsed targets. Thus, inhibition by free 1-10 
superimposed on  sensitization of targets  by  1-10  led  to  a 
relatively flat net dose-response curve  over a  wide range, 
with less net killing than was seen with the longer peptide. 
Free peptide inhibition could also be observed in  another 
system, using a  different epitope  (AH2-I9: residues 39-47 
from  the  HIV-1  reverse transcriptase restricted by the  K k 
MHC  molecule [data not shown]).  These results suggested 
that free epitopic peptides from the virus may inhibit spe- 
A 
i  i  ~  ~Smik.lmlB 
,~  --   2,0 
0  ......  -~ 
iii ,,o - 
Peptlde  ￿9  ~M) 
B 
I,o  ot  0 
c~ 
￿9  -.o..-  None 
IWB 
s  klO 
T.,.~  ....  :+. 
10  20  30  40  50  60  70 
Time  (Minutes) 
cific  CTL  activity against  virus-infected  targets,  and  this 
may be another mechanism of virus-specific CTL inactiva- 
tion in vivo. A  number of the experiments detailed below 
were  carried out with both  the  HIV  reverse transcriptase 
and envelope peptides with similar results, but for simplic- 
ity only the envelope peptide experiments are shown. 
Titration  and  Kinetics  of 1-10  Treatment for  CTL  Inhibi- 
tion.  To further investigate the mechanism of the inhibi- 
tion,  we  pretreated  the  CTL  line  or  clones with  various 
concentrations of I-10 for 1 h  in the absence of targets, and 
then  added these  cells to  the  assay culture  after complete 
removal of the  free peptide.  Profound  reduction  of CTL 
activity  was  observed  when  1-10-specific  CTL  lines  or 
clones were cocultured briefly with the free minimal pep- 
tide  1-10  at  >1  v,M,  and  half-maximal  inhibition  was 
achieved at between 0.01  and 0.1  I~M peptide for only 1 h 
(data  not  shown).  Surprisingly,  <10-min  pretreatment 
with 1 I~M of I-10 appeared to be sutticient to induce inhi- 
bition  (Fig.  1  B).  Shorter times  could not be investigated 
because of the  time required for centrifugation and wash- 
ing.  In  contrast,  although  1  I~M  of the  15-mer  peptide 
18IIIB showed some inhibitory activity with  1-h pretreat- 
ment (Fig. 1 B), >2 h  of treatment was necessary to gener- 
ate strong inhibition (Fig. 2 A  and data not shown). 
Requirement for Peptide Processing.  The  inhibition  could 
not be observed when 1-10 was presented to the CTL in an 
already ceU-associated form, either 1-10-pulsed BALB/c.3T3 
fibroblast  (Nee*I-10)  or  endogenously  synthesized  in  a 
gp160-transfected  BALB/c.3T3  flbroblast  (15-12)  (data 
not  shown  and  see  below).  These  results  suggested  that 
some processing steps are required for 18111]3 to be inhibi- 
Figure  1.  (A) Free epitopic peptides inhibit CTL activity in a dose- 
dependent manner. Either 5 X 103 untreated SiCr-labeled BALB/c.3T3 
fibroblast targets (O-O, [D-C]) or an equal number of P18lllB-prepulsed 
SlCr-labeled BALB/c.3T3 target cells ( 00,  It  ) were incubated with 
5 X 104 cells ofa P18IIIB-specific CTL line (LINE-IIIB) in the presence 
of various amounts of free antigenic peptides (P181IIB [[~O,  i-i  ] or 
1-10 [OgD, 0-0]) in 96-well round-bottom microtiter plates during the 
4 h assay. (B) Kinetics of 1-10 treatment for CTL inhibition.  106/m1 of 
LINE-IIIB cells  were incubated with 1 p,M 1-10 for various times at 37~ 
in complete T-cell medium (CTM)  ~ (25) and washed three times. Then 
5 ￿  104 treated LINE-IIIB cells were added to 5 ￿  10  3 of S~Cr-labeled 
P1811IB-prepulsed targets for 4 h. SEM of triplicate cultures was always 
<5% of the mean. 
1  Abbreviations used in this  paper: CTM, complete T-cell medium. 
Figure 2.  CTL inhibition by free peptide requires processing and pre- 
sentation of peptide by class I MHC molecules. (A) Captopril abrogates 
CTL inhibition by P18IIIB. 106/ml LINE-IIIB were incubated with 10  -5 
M captopril, a dipeptidase inhibitor that inhibits processing of P18IIIB to 
1-10 (26), together with 1 p~M P18IIIB or 1-10 overnight. Then the CTL 
were  washed three  times, and  5  ￿  10  4  treated LINE-IIIB  cells were 
added to 5 X 103 SlCr-labeled P18IIIB-prepulsed targets for 4 h. (B) Ef- 
fect of coculturing with competitor peptide during 4-h CTL assay. 5 X 
103 P18IIlB-prepulsed 51Cr-labeled  BALB/c.3T3 fibroblast targets were 
incubated with 5 X 104 P181IIB-specific  LINE-IIIB cells at the indicated 
concentrations of competitor peptide together with (0-0)  or without 
(O-O) 0.1 p,M 1-10 during the 4-h assay. SEM of triplicate cultures was 
always <5% of the mean. 
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surface MHC  molecules of the  CTL.  To  confirm this in- 
terpretation, we added the dipeptidase inhibitor captopril, 
which inhibits serum processing of 18IIIB to 1-10 (26),  to- 
gether with  either  18IIIB  or 1-10  in  an overnight culture 
with the CTL line, and found that captopril could abrogate 
the  inhibitory activity of 18IIIB but  not  1-10  (Fig.  2  A). 
These findings were reproducible in two additional experi- 
ments. Also, since captopril did not affect 1-10 inhibition of 
CTL activity, it should not be acting at other steps, such as 
peptide  binding  to  MHC.  In  addition,  inhibition  by 
18IIIB, but not by 1-10, requires the presence of FCS (data 
not  shown).  Thus,  proteolysis  of the  15-mer  peptide  is 
necessary for it to inhibit. Also consistent with presentation 
of processed peptide by D a as a requirement for inhibition, 
we found that treatment of CTL with mAbs specific for D a 
partially prevented the inhibition (data not shown). 
CTL Inhibition  Can  Be Partially Abrogated by  Competitive 
Peptide.  To  test  whether  inhibition  required  binding  of 
the free 1-10 to  the TCR  on the CTL and not just to the 
MHC  molecule,  we  synthesized  1-10  (325(V-Y))  with  a 
single substitution at position 325,  which  we  have  identi- 
fied as the major site for interacting with the TCR  (25, 27). 
We have previously demonstrated that HIV-1 IIIB--specific 
CTL  tend  to  see  aliphatic  amino  acids  at  position  325, 
whereas  MN-specific  CTL  see  aromatic  or  cyclic  amino 
acids  at  this  position  (38).  This  substituted  peptide  1-10 
(325(V-Y))  could not be recognized by IIIB-specific CTL 
at  all,  although  it binds  to  D d because  it can  he  seen  by 
MN-specific CTL with D a (data not shown).  Also, studies 
with sequentially added peptides indicated that the  substi- 
tuted  peptide  was  not  an  antagonist  (39-41)  (data  not 
shown).  Thus,  the peptide cannot  interact with the  TCR 
of IIIB-specific CTL  despite its binding to  the  D d class  I 
MHC  molecule.  As  shown  in  Fig.  2  B,  peptide  1-10 
(325(V-Y)) did not itself  inhibit, but competitively blocked 
the  inhibition induced by 1-10  in a  dose-dependent man- 
ner  during  the  4-h  CTL  assay  (Fig.  2  B).  Thus,  peptide 
must  bind to  both  the  MHC  molecule and  the  TCR  on 
the  CTL  to inhibit. Also, since the modified peptide can- 
not compete for binding to the TCR.,  this result also con- 
finns  that  inhibition is mediated by peptide-MHC  com- 
plexes and not direct binding of the peptide to the TC1K. 
I-lO-pulsed T  Cells Did Not Inhibit CTL Activity.  Since 
free  peptide  had  to  bind  to  the  appropriate class I  MHC 
molecule and be presented to the TCR  of the CTL being 
inhibited,  we  asked why peptide already bound  to  D d on 
fibroblasts did not  inhibit.  Perhaps  the  peptide  had  to  be 
presented  on  another  type  of cell.  Therefore,  we  pulsed 
1-10  onto  a  whole-spleen cell population, chosen to  have 
the  same  D a  molecule but  a  different H-2K  molecule  so 
that the cells could be depleted afterwards. We did not ob- 
serve  any  inhibition  when  the  CTL  were  cocultured for 
1 h  with  irradiated  B10.A  (D  d  and  K k)  spleen  cells 
prepulsed  with  1-10  and  then  treated  with  anti-K  k  mAb 
and rabbit C  to  remove B10.A cells (Fig. 3  A).  Some ap- 
parent cold-target inhibition by the  peptide-pulsed B10.A 
cells is eliminated when  these  are  removed.  These  results 
Figure 3.  Inabihty of spleen cells and other T cells to mediate peptide 
inhibition of CTL lines. (A) Effect of 1-10-pulsed B10.A spleen cells on 
LINE-IIIB inhibition. 5 ￿  106/ml B10.A  (D  a and K  k) spleen cells (APC) 
were incubated with 1 btM 1-10 for 1 h in CTM (25), 3,300 rad irradi- 
ated, washed three times, and mixed with 5 ￿  104 IllB-specific CTL line 
cells for another  1 h.  The mixed cells were then  treated with anti-K  k 
mAb and rabbit C to deplete B10.A cells and cocultured with  5 ￿  103 
SICr-labeled gp160-expressing BALB/c3T3 fibroblast (15-12) targets for 
4 h. (B) Effect ofcoculturing with 1-10-pulsed T cells on CTL inhibition. 
106/ii11 LINE-IIIB  were  cocultured  with  an  equal number  of CD8 § 
LINE-IIIB prepulsed for 1 h with I  ~M 1-10 or MNT10,  or with the 
P181IIB-specific CD4 + helper T cell line, HT-4, prepulsed with  1 ~M 
1-10 for  1 h. Where indicated, the mixed cells were then  treated with 
anti-CD4  mAb (RL174) and rabbit C to deplete the CD4 + HT-4 line. 
Then  the  effector cells were  cocultured  with  5  ￿  103  SlCr-labeled 
P18IllB-prepulsed targets for 4 h. SEM of triplicate cultures was always 
<5% of the mean. 
were  reproducible  in  three  experiments.  These  data 
strongly indicated that the free peptide 1-10 does not work 
via binding  to  APC  contamination  in  the  CTL  line,  but 
only by binding to the CTL themselves. These data also ar- 
gue  against  inhibition by veto  cells  in  the  spleen,  which 
should  inhibit  the  CTL  to  which  they  present  peptide. 
Failure to  see such  a  veto phenomenon  is consistent with 
the resistance of CTL clones to veto (23). 
If the free peptide requires processing so that it can bind 
to MHC  molecules, but does not act when bound to other 
cells,  it  may  have  to  be  presented  by  T  cells  to  inhibit. 
Therefore, we tested the effect ofpresention by other CD4 + 
or  CD8 +  T  cells. Taking advantage  of the  Da-expressing 
CD4 + helper T  cell line, HT-4 (6), 1-10-specific CTL line 
(LINE-IIIB)  cells  were  mixed  with  an  equal  number  of 
1-10-pulsed  HT-4  or  an  equal  number  of  1-10-pulsed 
LINE-IIIB  cells  before  being  added  to  the  51Cr-labeled 
Neo*l-10  targets  for  the  4-h  assay culture.  In  contrast  to 
unpulsed  HT-4,  1-10--pulsed HT-4  significantly inhibited 
the  activity  of  LINE-IIIB,  whereas  1-10-pulsed  CD8 + 
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found that LINE-IIIB did efficiently kill 51Cr-labeled HT-4 
cells  when  pulsed  with  1-10,  whereas  they  did  not  lyse 
SlCr-labeled  1-10-pulsed  LINE-IIIB  as  targets  (data  not 
shown). Thus, we speculated that 1-10-pulsed HT-4 prob- 
ably  acted  as  cold  target  inhibitors  in  the  assay  culture. 
Therefore,  we  depleted  the  culture  of 1-10-pulsed  HT-4 
cells by treatment with rat anti-mouse CD4 mAb (R.L174) 
plus rabbit  C  after  a  2-h incubation with LINE-IIIB, and 
then  added the  residual  LINE-IIIB to the assay system for 
an  additional  4  h.  Depletion  of 1-10-pulsed  HT-4  cells 
completely  abrogated  the  inhibition.  This  result,  repro- 
duced in two additional experiments,  suggests that the pep- 
tide,  1-10, does not inhibit specific CD8 + CTL when pre- 
sented by their fellow CD8 + T  cells, and the inhibition by 
1-10-pulsed  CD4 §  T  cells  appears  to  be  by  a  different 
mechanism,  cold-target inhibition,  which does not explain 
the effect of free peptide on CTL. This result also excludes 
a classic veto mechanism,  in which CD8  §  cells presenting 
peptide to the TCR  ofa CTL inhibit it (11, 21-23). 
Fratricide May Not Be the Cause of Inhibition.  These  re- 
sults  demonstrate  that free antigenic  peptide  must bind  to 
the  MHC  molecule  on  the  surface  of effector  CTL  to 
downregulate their cytolytic activity. To distinguish whether 
the mechanism of  inhibition was CTL fratricide, suicide, or 
anergy induced  when  the  TCP,  interacts  with  a  peptide- 
MHC  complex on the  surface  of the  CTL itself,  we 51Cr 
labeled some of the same CTL line as targets and found that 
they did not kill each other in the presence of free peptide 
(data  not shown).  Moreover,  in  mixing experiments  with 
two  non-cross-reactive  CD8  +  CTL lines  (LINE-IIIB and 
LINE-MN)  specific for two homologous peptides,  18IIIB 
(or  1-10)  and  18MN  (or MNT10)  from  different  HIV-1 
isolates,  both  presented  by  the  same  MHC  molecule, 
H-2D  d, we found that the presence  of free peptide  recog- 
nized by one CTL line but able to bind to H-2D  a on both 
CTL lines did not inhibit the cytolytic activity of the other 
syngeneic  CTL line  for its  targets,  as  would  be  expected 
if the  mechanism  had  been  fratricide  (Fig.  4,  reproduced 
in three  additional  experiments).  Furthermore,  MNT10- 
prepulsed  LINE-IIIB was not inhibited  at all  when cocul- 
tured  with  LINE-MN  and,  conversely,  1-10-prepulsed 
LINE-MN was not inhibited when cocultured with LINE- 
IIIB (see  Fig.  5).  Thus,  the mechanism of CTL inhibition 
by the free epitopic peptide appears not to be fratricide, in- 
hibition by one T  cell of another T  cell presenting the spe- 
cific peptide, or the release of inhibitory cytokines. Rather, 
it appears that the peptide must be presented on the T  cell's 
own MHC  molecules, to the cell's own TCR  specific for 
that peptide-MHC  complex. 
Dual Engagement Requirement.  The  possibility  remained 
that simultaneous  occupancy of both the TCR  and MHC 
molecule on the CTL was all that was required,  so that two 
CTL lines specific for different peptides on the same MHC 
molecule could inhibit  each other if each was pulsed with 
the peptide for which the other CTL was specific and they 
were washed and mixed.  This  experiment  differs from the 
previous one in that the CTL presenting one peptide in its 
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Figure 4.  Fratricide  is not the cause of inhibition by free peptide. 5 )< 
104 treated cells of LINE-IIIB and/or LINE-MN were added to 5 ￿  10  3 
StCr-labeled P18llIB-prepulsed targets (A) or P18MN-prepulsed targets 
(/3) in the presence of either 1 ~M of See P18IIIB (I-10) or an equal 
amount of free P18MN (MNT10) for 4 h. SEM of  triplicate cultures was 
always <5% of  the mean. 
MHC molecule also can engage its TCP, with the peptide- 
MHC  on  the  other  T  cell  at  the  same  time.  To  test  this 
possibility,  we  mixed  LINE-MN  pulsed  with  1-10  and 
LINE-IIIB pulsed with MNT10 and found that both were 
inhibited  (Fig.  5),  tested  on  their  respective  targets.  Only 
this  configuration  of pulsed  cells  showed inhibition.  This 
inhibition  in  trans appears  less  efficient than  in cis, that  is, 
when the TCR  was engaging the peptide-MHC  complex 
on the same cell, but was reproducible  and statistically sig- 
nificant.  In eight inhibition  experiments  in  four indepen- 
dent studies similar to the  one shown in  Fig.  5, the  mean 
percentage  of inhibition  was 40.3  +  2.69%  (P <0.001  by 
Student's t test). Thus, the mechanism of  inhibition appears 
to require that both the MHC  molecules and the TCP,.s of 
the CTL be engaged simultaneously  ("dual engagement"), 
either  on the  same  cell  or in a  conjugate between  two or 
more  cells.  This  dual  engagement  mechanism  is  reminis- 
cent of, but distinct from, the veto process (see Discussion). 
I-lO-treated  CTL Activity  Could  Be  Partially Restored by 
Restimulation.  If the mechanism of inhibition were apop- 
tosis of CTL, cytotoxic activity should not be recovered by 
restimulation,  whereas  if it were anergy,  activity might be 
recoverable. Both the downregulated CTL line (Fig. 6) and Figure 5.  Dual engagement may be the cause ofinkibition  by free pep- 
tide. 2 ￿  106/ml non-cross-reactive  CTL lines, LINE-IIIB and LINE-MN 
(P18MN-specific CTL line), were pretreated with either  1 ~M 1-10 or 
MNT10 for 1 h at 37~  After being washed three times, 5 ￿  104 treated 
cells of LINE-1IIB and/or LINE-MN were added to 5 ￿  103 SlCr-labeled 
1-10-prepulsed targets (A) or MNT10-prepulsed targets (/3) for 4 h. SEM 
of triplicate cultures was always <5% of the mean. 
clone RT-3  (not shown)  treated with  1  liM 1-10 for  1  h 
could be restored to almost 80% of their original activities 
by restimulation with  1-10-expressing BALB/c  fibroblasts 
even 2  d  after the  free peptide  treatment  (reproducible in 
three  experiments).  Even if the  cells were  pretreated  with 
1-10 for a  full 24  h  and then restimulated with the  gp160 
transfectant 15-12,  83% of the activity could be recovered 
(data not shown). This result suggests that the major mech- 
anism of inhibition is  temporary  self-inactivation (anergy) 
rather  than  apoptosis  (suicide).  We  also  could  not  detect 
any DNA  ladders in the CTL treated with 1-10 for 2  h  and 
Figure 6,  CTL inhibited by free 1-10 can be partiaUy restored by re- 
stimulation  with  1-10-expressing  cells. 4  ￿  106/ml  LINE-IIIB were 
treated with 1 p.M off-10 for 1 h and washed three times. After 1 or 2 d 
further incubation  at  106/1Ill,  treated cells were restimulated with 10S/ml 
mitomycin C-treated 1-10-expressing syngeneic BALB/c 3T3 fibroblasts 
together with IL-2 for another 5 d in a 24-well culture plate, harvested, 
and  tested  for  their  cytolytic  activities  against  5  X  t03  SlCr-labeled 
Pl8IllB-prepulsed targets at an E/T ratio of20:l. SEM of triplicate cul- 
tures was always <5% of the mean. 
Figure 7.  Downregulation  of  surface markers on the CTL treated with 
free 1-10. 106 cells were  incubated  for  1 h  with free 1-10 and washed 
three  times.  Then  1  ~g  of the  indicated  FITC-labeled antibody was 
added to the cell pellet for a 40-min incubation at 4~  The cells were 
washed three  times and resuspended at  106 cells/0.5  ml in PBS/BSA/ 
azide for analysis  by FACScan  | 
then  cultured without  peptide  for  an  additional  24  h,  or 
pulsed with 1-10 for a full 24 h  (data not shown). 
Downregulation of Surface Markers on the CTL Treated with 
Free 1-10.  As  a  clue  to  a  possible inhibitory mechanism, 
we  found that free  1-10 induced apparent downregulation 
of expression  of specific  TCR  (V[38.1  on clone RT-2  or 
ILT-3  [Takahashi,  H.,  and Y.  Nakagawa,  unpublished ob- 
servation])  as  well as CD3,  IL-2R  (ee, and [3 not shown), 
CD69  (activated  T  cell marker),  LFA-1  (not shown),  and 
CD8  (Fig. 7). However,  class I MHC  molecules such as D a 
(Fig.  7),  K a,  or  L a  (data  not  shown)  did  not  show  any 
downmodulation on the 1-10-treated CTL. The same pat- 
tern  of downregulation was  seen  in five  independent ex- 
periments,  as  well  as  one  in  which  the  cells  were  main- 
tained  in suspension  (albeit  to  a  slightly lesser  extent).  It 
was  also  observed  after 24  h  of exposure  to  1-10,  and the 
expression remained partially downregulated 24 h  after a  1-h 
exposure (data not shown). The lack of effect on class I MHC 
molecules suggests that  the  FACS  |  analysis results are  not 
merely caused by downsizing of the  cells  or a  generalized 
effect on all surface molecules. Thus, the inhibition of CTL 
activity  is  concurrent  with  a  downmodulation  of surface 
activation markers and specific TCR,  the latter resembling 
that reported for CD4 + class II MHC-restricted T  cells ex- 
posed to high concentrations of specific peptide  (17). 
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In this study, we found that exposure of CD8 + CTL to a 
peptide corresponding to the minimal epitope, free in solu- 
tion,  leads to strong inhibition  of the  cytolytic activity of 
the epitope-specific CTL. Our data suggest that this effect 
requires dual engagement of TCP,. and MHC molecules on 
the same T  cell and involves downregulation of TCR. and 
several  other  surface  molecules  without  cell  death.  Al- 
though shown to be distinct from the classic  veto mecha- 
nism (21-24),  which does not act on long-term CTL fines 
and  clones  in  vitro,  the  dual  engagement  requirement  is 
nevertheless rather analogous to the veto mechanism on a 
molecular level, so that the inhibition by free peptide may 
be considered a self-veto process, as discussed below. 
Several papers  have reported  that  free epitopic peptide 
can  inhibit  the  specific  activities  of CD8 +  CTL  (7-11). 
However, the mechanism of the inhibitaon is still  contro- 
versial, and previous studies have not examined a dual en- 
gagement requirement.  Suet  al.  (13)  concluded  that  the 
mechanism of inhibitaon by fr~e cognate peptide is "fratri- 
cide" rather than "suicide" (8, 9,  12) based on experiments 
using  CTL  isolated  with  the  microdrop  separation  tech- 
nique using gel agarose. However, although no killing was 
observed in the isolated cells in microdrops, functional an- 
ergy could not be tested. Thus, there is no real discrepancy 
with our study, in which we observe anergy but not kill- 
ing, and in which the process appears to be able to occur in 
single cells. LaSalle et al. (42) observed that anergy required 
cell contact when peptides presented by class II MHC mol- 
ecules were used,  but it is not clear that the mechanism is 
the same as described here for class I MHC presentation. If, 
as our data suggest, either a single cell or two-cell mecha- 
nism  can  occur,  one  or  the  other  may predominate  de- 
pending  on cell density and peptide  concentration.  Thus, 
the differences among the studies may be explained, at least 
in part, by differences in these parameters. Also, as Suet al. 
(13)  point out, the requirements for anergy may be differ- 
ent from those for cell death.  For example, the study dem- 
onstrating fratricide was carried out at 107-fold higher pep- 
tide  concentration  than  required  for 50%  tysis  of targets, 
whereas the  anergy induction  occurred in a peptide  con- 
centration range similar to that required for target sensitiza- 
tion (Fig.  l  A). Thus, high dose inhibition may be playing 
a role in some studies  and not others,  invoking a mecha- 
nism different from that of free peptide at lower concentra- 
tions. 
To investigate fratricide as a mechanism in  our system, 
we used  two distract  and  non-cross-reactive CD8 +  CTL 
lines, LINE-ItIB and LINE-MN, specific for the homolo- 
gous peptides  1-10  (18IIIB) or MNT10  (18MN),  respec- 
tively,  and restricted by the  same class  I  MHC molecule, 
H-2D  a. We did not detect any ;inhibition when the LINE- 
IIIB cells were prepulsed or mixed with soluble  18MN or 
MNTI0  and cocultured with LINE-MN cells  that should 
kill such peptide-pulsed LINE-IIIB cells  if the mechanism 
were fratricide,  and vice versa in the  reciprocal combina- 
taon. Moreover, when half the CTL line cells  were pulsed 
with the peptide for which  they were specific and cocul- 
tured with the other half, the cytolytic activity of the un- 
pulsed cells was not inhibited.  These results exclude a clas- 
sic veto mechanism (11,  21-24). In addition, we confirmed 
that 51Cr-labeled 1-10--pulsed CD8 § CTL are not killed by 
LINE-IIIB, consistent with resistance of CTL to lysis (2-4). 
We conclude that fratricide is not the mechanism of inhibi- 
tion in our system. 
Furthermore, we have shown that 1-10-treated CTL can 
be restored to almost 80% of their original activity by re- 
stimulation 2 d after peptide treatment. This result and the 
absence of obvious DNA ladders in the  treated CTL also 
strongly suggest that the principal mechanism is not suicide. 
Taken together, these results suggest that the major mecha- 
nism of inhibition,  under our conditions,  is transient self- 
inactivation (anergy or paralysis),  not cell death. This inter- 
pretation is consistent with the downregulation of receptors 
we observed. However, it should be noted that the differ- 
ence  between  cell  death  and  anergy may depend  on  the 
state of the CTL in the conditions of the experiment, such 
as their bcl-2 levels, so that either outcome may be possible 
under different circumstances, even when the signaling mech- 
anism is the same. 
The effect of peptide length may be an important vari- 
able not analyzed in previous studies that may explain some 
differences in results.  Here we show that longer peptides, 
such  as  18IIIB, need  processing by protease(s)  present  in 
FCS that can be inhibited by specific inhibitors such as cap- 
topril (26); thus, only the optimal-sized peptide, such as 1-10, 
caused rapid and strong inhibition of CTL activity, whereas 
it takes >2 h  for the  15-residue peptide  18IIIB to inhibit. 
Therefore, some discrepancies between studies may be due 
to use of longer peptides to analyze the inhibitory mecha- 
nism.  For  example,  the  difference  between  the  FACS  ~ 
analysas data of Robbins and McMichael (10) and ours may 
come from the length of the peptide used in the assay,  in 
that they demonstrated downmodulation  of CD8 but not 
of IL-2 receptor or TCR  in  the  presence of free  13-mer 
peptide from influenza nucleoprotein, which required 10 h 
for inhibition  and was more variable, as we have seen for 
the 15-mer 18IIIB. 
To better understand the minimal signaling requirements 
for free peptide  to inhibit,  we also studied  the  efficacy of 
other APC in inducing the inhibition.  First,  we found that 
BALB/c.3T3  fibroblasts expressing  1-10,  either  externally 
pulsed or internally synthesized, did not inhibit the activity 
of specific CD8 § CTL. Second, 1-10-pulsed Dd-expressing 
whole spleen ceils from B10.A mice, containing a  variety 
of APC,  did not affect the  CTL activity when the B10.A 
cells  were removed before the SICr-release assay to  avoid 
cold-target blocking.  (Since the spleen ceils also contain T 
cells  that could act as veto cells,  these  results also  help  to 
exclude a classic veto cell mechanism [11,  21-24].)  Third, 
we found that presentation of 1-10 by the BALB/c CD4 + 
Th cell line, HT-4, did not inhibit CD8 + CTL, except by 
cold-target inhibition,  which  could be eliminated by de- 
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could not be killed when pulsed with peptide also did not 
act  as  cold  targets  and  did  not  inhibit.  Time-dependent 
morphological changes  in  isolated CTL  with  free peptide 
(data not shown),  similar to the morphological change ob- 
served by Walden and Eisen  (8),  if indicative of the same 
phenomenon,  also exclude cold target inhibition by other 
CTL and suggest action at the single cell level. Thus,  pre- 
sentation of peptide by any other cell does not mimic the 
effect of free peptide. 
Nevertheless, the data indicate that the free peptide does 
not act in the free state, but must be presented by a  class I 
MHC  molecule.  Captopril  abrogation  of  inhibition  by 
18IIIB  but  not  1-10  suggests  that  the  inhibition  requires 
binding of the minimal peptide to the class I  MHC  mole- 
cule on the  CD8 +  CTL.  This  conclusion is supported by 
partial blocking of inhibition by pretreatment of CTL with 
anti-D  d (data not shown)  and by the fact that a  noninhibi- 
tory, nonantagonistic 1-10 variant with a single substitution 
at a key TCl~-interacting site competed against the inhibi- 
tory activity of the unmodified 1-10. The modified peptide 
could not compete for binding to the TCP, because it had 
neither  agonist  nor  antagonist  activity despite  binding  to 
D a.  Thus,  competition must be for binding to  the  MHC 
molecule, a further indication that free peptide has to bind 
to the MHC  molecule to inhibit. Vitiello et al. (7) similarly 
concluded that the peptide must be presented on the MHC 
molecule  of the  CTL  itself from  experiments  using  D b- 
restricted  influenza  nucleoprotein-specific  CTL  derived 
from  chimeric  mice  in  which  the  CTL  were  of different 
genetic  origin  not  expressing D b.  However,  the  fact  that 
CTL-CTL  presentation of peptide did not produce  cold- 
target inhibition, and the inability of this mechanism to ex- 
plain the downregulation of multiple surface molecules on 
the  CTL,  make  cold-target inhibition of a  single CTL by 
its  own  MHC  molecules presenting peptide  (7)  unlikely. 
Taken together, these results, which demonstrate a require- 
ment for binding to the class I MHC  molecule but exclude 
presentation  on  other  cells, indicate  that  the  free  peptide 
must be presented on  the  CTL  themselves to induce spe- 
cific CD8 + CTL inhibition. 
How then does presentation of the peptide on the CTL's 
own MHC  molecules differ from presentation on the same 
MHC  molecule of another cell? The experiments in which 
CTL  of different specificity but  similar MHC  restriction, 
pulsed  with  each  other's  peptide,  can  inhibit  each  other 
(Fig.  5),  in  contrast to  the  case  in  which  the  peptide for 
only one of the CTL is present (Fig. 4), show that the min- 
imal requirement for inhibition is simultaneous occupancy 
of the TCI< and MHC  molecule on the  CTL.  This  dou- 
ble-pulsing  experiment  of  Fig.  5  creates  a  situation  in 
which the CTL cannot see the peptide on their own MHC 
molecules, but must see it on  another  CTL,  and yet each 
CTL has both its MHC  molecules and TCP, engaged (Fig. 
8  B).  It allows us to conclude that such simultaneous dual 
engagement  of MHC  and  TCP,.  on  the  same  cell  is  re- 
quired. In the normal circumstance with a single CTL line 
and a single peptide, this situation can occur between pairs 
of the same CTL at high density incubated with free pep- 
tide (Fig. 8  C), as well as on isolated single cells (Fig. 8 A). 
When cells of the same clone are not together at high den- 
sity,  as  may  often  be  the  case  in  nature,  the  single-cell 
mechanism may be the only one available. Presentation in 
the  same  cell  is  possible  because  the  cell  surface  is  not 
smoothly convex,  but has many projections and invagina- 
tions,  and independent  evidence for such  a  functional in- 
teraction has been obtained (Koenig, S., personal commu- 
nication).  If a  mixture  of peptides  and  CTL  specific  for 
them occurs, as during lysis ofvirally infected cells, the sit- 
uation in Fig. 8  B,  as created in  the  experiment shown  in 
Fig.  5,  may  also  arise.  Thus,  our  results  suggest  that  the 
most  hkely  mechanism  of this  inhibition  may  be  signal 
transduction within the CTL by having its TCP,. ligated to 
its own MHC  molecules in cis or in a reciprocal interaction 
with a  sister cell's TCP,  and MHC  molecules in  trans,  re- 
suiting in  reversible downregulation  of surface  molecules. 
Figure 8.  Model of the self-veto or dual engagement mechanism of 
CTL inactivation by free peptide. The data indicate that the minimal re- 
quirements for free peptide to inactivate CTL  are simultaneous occu- 
pancy of  the class I MHC molecule and the TCP- on the same CTL. This 
may occur in an isolated cell when the TCP, of a cell binds the peptide- 
MHC complex formed on the same cell (A). Because the cell surface is 
not smooth, but has many projections and invaginations,  TCP,. and MHC 
molecules on the same cell can easily come into contact. Alternatively, 
the same simultaneous engagement of TCP, and MHC may occur be- 
tween two cells. In the experiment shown in Fig. 5, in which two non- 
cross-reactive  CTL lines were pulsed with each other's peptide, it can oc- 
cur only when two cells of opposite types come together and recognize 
their peptides on the other cell's MHC molecules (B). However, in the 
simpler situation with a single CTL and a single free peptide, two sister 
cells each binding the peptide may inactivate each other (C). Whether the 
upper single-cell  or the lower two-cell mechanism predominates may de- 
pend on cell density. 
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cule on the same T  cell appears to inhibit. 
Recendy,  signaling  though  MHC  class  I,  such  as  by 
cross-linking with  specific antibodies,  has been shown  to 
regulate  signal transduction  though  the  TCR.--CD3  com- 
plex and can lead to inhibition of cellular function (43), in- 
cluding cytotoxicity (44), perhaps by prolonging the dura- 
tion ofa CD3-induced elevation in intracellular Ca  2+ (45). 
Sustained increases in intracellular Ca  2§  can  often lead  to 
unresponsiveness in CTL (46);  consequendy, MHC class I 
modification of TCR-CD3  signals  may represent another 
mechanism  for  the  induction  of anergy.  T  cell  signaling 
through the class I molecule does not depend on the MHC 
cytoplasmic domain (47),  but instead requires association of 
class  I  protein with  other cell surface molecules  (48,  49). 
Most studies of MHC class I signal transduction and regula- 
tion of CTL effector function have involved the use of an- 
tibodies as an MHC cross-linking agent. In our system, en- 
gagement  of MHC  class  I-peptide  complex  on  a  CTL 
instead by a TCR may lead to anergy via MHC class I reg- 
ulation  of TCR  signaling events.  This mechanism of an- 
ergy induction  appears  to  be  distinct  from that  of TCR 
triggering in the absence ofa costimulatory signal (19,  50). 
The requirement for simultaneous signaling through the 
TCR and MHC molecule on the same CTL is reminiscent 
of the  molecular mechanism proposed  for the  veto phe- 
nomenon  (23,  24).  The  TCR  of the  CTL being vetoed 
must bind  the  MHC  molecules of the  veto  cell,  and  the 
CD8 molecule of the veto cell binds the o~3 domain of class 
I MHC molecules of the CTL. Thus, the CTL has both its 
TCIk and  its  class  I  MHC  molecules engaged.  The  dual 
engagement permitted by free peptide  may be a  stronger 
signal through the MHC molecule, involving the interac- 
tion  of TCR.  rather  than  CD8  with  the  peptide-MHC 
complex,  and  thus  may account  for inhibition  of T  cell 
clones  resistant  to  classic  veto.  Nevertheless,  the  require- 
ment  for  concurrent  engagement of both  molecules  is  a 
clear parallel. We are not aware of any previous connection 
made  between  free peptide  inhibition  and  the  veto phe- 
nomenon, but on the basis of the results presented here, we 
propose that free peptide inhibition of CTL activity is actu- 
ally a process of self-veto. 
There are a number of potential mechanisms of inhibi- 
tion of virus-specific CTL in HIV-l-infected patients. We 
have observed a similar inhibitory effect of free peptide in 
vivo in primed animals (Takahashi, H., and Y. Nakagawa, 
unpublished  observations), and Walden  and Eisen  (8)  also 
observed a  similar loss  of CTL activity in  spleen  cells  of 
primed animals after injection of an OVA peptide. Perhaps 
when vitally infected cells are lysed and the digested intra- 
cellular proteins  released  into  the  environment  of the  T 
cell, anergy may be induced and clearance of the virus from 
other infected cells prevented. Thus,  the self-veto mecha- 
nism shown here may contribute to inactivation of virus- 
specific CTL in vivo and virus persistence, and, conversely, 
restoration  of such  inactivated  CTL  may  prevent  virus 
spread and disease progression. 
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